Cargando…
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419350/ https://www.ncbi.nlm.nih.gov/pubmed/30918533 http://dx.doi.org/10.1186/s13053-019-0109-5 |
_version_ | 1783403924682702848 |
---|---|
author | Menkiszak, Janusz Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Celewicz, Aleksander Kojs, Zbigniew Szajda, Mariusz Świniarska, Maria Bedner, Ryszard Jurczak, Anna Celewicz, Marta Cieszyńska, Monika Lubiński, Jan Gronwald, Jacek |
author_facet | Menkiszak, Janusz Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Celewicz, Aleksander Kojs, Zbigniew Szajda, Mariusz Świniarska, Maria Bedner, Ryszard Jurczak, Anna Celewicz, Marta Cieszyńska, Monika Lubiński, Jan Gronwald, Jacek |
author_sort | Menkiszak, Janusz |
collection | PubMed |
description | BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics of these neoplasms are not well known. In this study, we determined the selected parameters such as age at cancer diagnosis, time from RRSO to the diagnosis of cancer, and significance of BRCA1 mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up. METHODS: The material comprised of 195 BRCA1 carriers who performed RRSO between years 1999–2012. In this period, 16 patients developed cancer (6-primary breast cancer, 3-contralateral breast cancer, 5-relapse of breast cancer, 2-peritoneal cancer). They were subject of the further analysis. RESULTS: During the follow-up period mean age of patients after RRSO at the time of cancer diagnosis was 53.19. The mean age of patients diagnosed with primary breast cancer was 50, contralateral breast cancer – 58.67, recurrence of breast cancer - 51 and peritoneal cancer 60. The mean time periods from RRSO to the diagnosis of primary, contralateral, recurrence breast cancer were 53, 58.67 and 25,4 months respectively and of peritoneal cancer 46 months. BRCA1 c.5266dupC mutation carriers demonstrated significantly shorter time of cancer development compared to patients carrying c.181T > G and c.4035delA mutations. Peritoneal cancer was only observed in two c.181T > G BRCA1 mutation carriers. CONCLUSIONS: The mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupC BRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively. |
format | Online Article Text |
id | pubmed-6419350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64193502019-03-27 Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy Menkiszak, Janusz Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Celewicz, Aleksander Kojs, Zbigniew Szajda, Mariusz Świniarska, Maria Bedner, Ryszard Jurczak, Anna Celewicz, Marta Cieszyńska, Monika Lubiński, Jan Gronwald, Jacek Hered Cancer Clin Pract Research BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics of these neoplasms are not well known. In this study, we determined the selected parameters such as age at cancer diagnosis, time from RRSO to the diagnosis of cancer, and significance of BRCA1 mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up. METHODS: The material comprised of 195 BRCA1 carriers who performed RRSO between years 1999–2012. In this period, 16 patients developed cancer (6-primary breast cancer, 3-contralateral breast cancer, 5-relapse of breast cancer, 2-peritoneal cancer). They were subject of the further analysis. RESULTS: During the follow-up period mean age of patients after RRSO at the time of cancer diagnosis was 53.19. The mean age of patients diagnosed with primary breast cancer was 50, contralateral breast cancer – 58.67, recurrence of breast cancer - 51 and peritoneal cancer 60. The mean time periods from RRSO to the diagnosis of primary, contralateral, recurrence breast cancer were 53, 58.67 and 25,4 months respectively and of peritoneal cancer 46 months. BRCA1 c.5266dupC mutation carriers demonstrated significantly shorter time of cancer development compared to patients carrying c.181T > G and c.4035delA mutations. Peritoneal cancer was only observed in two c.181T > G BRCA1 mutation carriers. CONCLUSIONS: The mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupC BRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively. BioMed Central 2019-03-14 /pmc/articles/PMC6419350/ /pubmed/30918533 http://dx.doi.org/10.1186/s13053-019-0109-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Menkiszak, Janusz Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Celewicz, Aleksander Kojs, Zbigniew Szajda, Mariusz Świniarska, Maria Bedner, Ryszard Jurczak, Anna Celewicz, Marta Cieszyńska, Monika Lubiński, Jan Gronwald, Jacek Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title | Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title_full | Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title_fullStr | Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title_full_unstemmed | Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title_short | Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy |
title_sort | selected features of breast and peritoneal cancers diagnosed in brca1 carriers after risk-reducing salpingo-oophorectomy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419350/ https://www.ncbi.nlm.nih.gov/pubmed/30918533 http://dx.doi.org/10.1186/s13053-019-0109-5 |
work_keys_str_mv | AT menkiszakjanusz selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT chudeckagłazanita selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT cymbalukpłoskaaneta selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT celewiczaleksander selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT kojszbigniew selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT szajdamariusz selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT swiniarskamaria selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT bednerryszard selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT jurczakanna selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT celewiczmarta selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT cieszynskamonika selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT lubinskijan selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy AT gronwaldjacek selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy |